FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어
N6-methyladenosine regulated FZD7 inhibits ferroptosis in endometriosis via β-catenin/SLC7A11 pathway.
Endometriosis (EMS), a chronic inflammatory disease affecting approximately 10% reproductive aged women, remains etiologically unclear. This study aims to investigate the role and underlying mechanisms of frizzled class receptor 7 …
The efficacy of adjuvant therapies in improving endometrial function of women undergoing assisted reproductive technology: a systematic review and network meta-analysis - BMC Pregnancy and Childbirth
The efficacy of adjuvant therapies in improving endometrial function of women undergoing assisted reproductive technology: a systematic review and network meta-analysis BMC Pregnancy and Childbirth
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - BioSpace
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma BioSpace